Argos Therapeutics Inc. reported on an update on the interim analysis of data from the ongoing phase III ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma was presented by Robert Figlin, professor and chairman, division of hematology and oncology at Cedars Sinai Medical Center, and co-principal investigator of the ADAPT trial at the European Society for Medical Oncology 2017 Congress in Madrid.
Knowledge is power, and this information, true for many cancers, is valuable for everyone to know—either to have an awareness of their own bodies and the factors that they can control, or to create spaces for empathy with persons they might encounter with cancer.
